The global tuberculosis situation and the inexorable rise of drug-resistant disease

Advanced Drug Delivery Reviews

Volumn 102, Issue , 2016, Pages 3-9

  Marais, Ben J ^a,b  

^a University of Sydney   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Drug resistant tuberculosis; Epidemiology; Transmission

Indexed keywords

COST EFFECTIVENESS; DISEASE CONTROL; EPIDEMIOLOGY; TRANSMISSIONS;

CONTROL EFFORT; DRUG-RESISTANT STRAINS; DRUG-RESISTANT TUBERCULOSIS; EPIDEMIC SPREAD; INFECTION CONTROL; MOLECULAR EPIDEMIOLOGY; TRANSMISSION CYCLES; VACCINE DEVELOPMENT;

CONTROLLED DRUG DELIVERY;

BCG VACCINE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL TRANSMISSION; DELAYED DIAGNOSIS; DRUG EFFICACY; DRUG RESISTANT TUBERCULOSIS; DRUG TREATMENT FAILURE; EPIDEMIC; HEALTH CARE SYSTEM; HUMAN; INCIDENCE; POLITICS; PRIORITY JOURNAL; REVIEW; THERAPY DELAY; TUBERCULOSIS CONTROL; VACCINATION; FORECASTING; MULTIDRUG RESISTANT TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DISEASE OUTBREAKS; FORECASTING; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84964381012     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.01.021     Document Type: Review

References (57)

1. Fox W., Wiener A., Mitchison D.A., Selkon J.B., Sutherland I. The prevalence of drug-resistant tubercle bacilli in untreated patients with pulmonary tuberculosis: a national survey 1955-56. Tuberculosis 1957, 38:71-84.
2. Marais B.J., Raviglione M., Donald P.R., et al. Scale-up of services and research priorities for diagnosis, management and control of tuberculosis - call to action. Lancet 2010, 375:2179-2191.
3. Global Tuberculosis Report World Health Organization, Geneva. 2015, (Switzerland).
4. Abubakar I., Ford N., Cox H., et al. The rising tide of drug-resistant tuberculosis - time for visionary leadership. Lancet Infect. Dis. 2013, 13:529-539.
5. Udwadia Z.F., Amale R.A., Ajbani K.K., Rodrigues C. Totally drug-resistant tuberculosis in India. Clin. Infect. Dis. 2012, 54:579-581.
6. Zhao Y., Xu S., Wang L., et al. National survey of drug-resistant tuberculosis in China. N. Engl. J. Med. 2012, 366:2161-2170.
7. Zhang Z., Lu J., Wang Y., Pang Y., Zhao Y. Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. Antimicrob. Agents Chemother. 2014, 58:364-369.
8. Wei-wei Jiao W., Liu Z., Han R., et al. Prevalence of drug resistant Mycobacterium tuberculosis among children in China. Tuberculosis 2015, 95(95):315-320.
9. Skrahina A., Hurevich H., Zalutskaya A., et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur. Respir. J. 2012, 39:1425-1431.
10. Sanchez-Padilla E., Merker M., Beckert P., et al. Detection of drug-resistant tuberculosis by Xpert MRB/RIF in Swaziland. N. Engl. J. Med. 2015, 372:1181-1182.
11. Gurjav U., Jelfs P., Hill-Cawthorne G.A., Marais B.J., Sintchenko V. Genotype heterogeneity within geospatial hotspots suggest foci of imported disease in Sydney, Australia. Infect. Genet. Evol. July 15 2015, (E-pub ahead of print).
12. Oestreicher R., Dressler S.H., Russel W.F., Grow J.G., Middlebrook G. Observations on the pathogenicity of isoniazid resistant mutants of tubercle bacilli for tuberculosis patients. Am. Rev. Tuberc. 1955, 71:390-405.
13. Cohen T., Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat. Med. 2004, 10:1117-1121.
14. Borrell S., Gagneux S. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 2009, 13:1456-1466.
15. Toungoussova O.S., Caugant D.A., Sandven P., Mariandyshev A.O., Bjune G. Impact of drug resistance on fitness of Mycobacterium tuberculosis strains of the W-Beijing genotype. FEMS Immunol. Med. Microbiol. 2004, 42:281-290.
16. Schaaf H.S., Marais B.J., Hesseling A.C., Brittle W., Donald P.R. Surveillance of antituberculosis drug resistance amongst children from the Western Cape Province of South Africa - an upward trend. Am. J. Public Health 2009, 99:1486-1490.
17. Child MDR-TB atlas. (last accessed 20 August 2015). http://www.treatmentactiongroup.org/tb/publications/2013/we-can-heal.
18. Casali N., Nikolayevskyy V., Balabanova Y., et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat. Genet. 2014, 46:279-286.
19. Marais B.J., Mlambo C.K., Rastogi N., et al. Epidemic spread of multidrug-resistant (MDR) tuberculosis in Johannesburg, South Africa. J. Clin. Microbiol. 2013, 51:1818-1825.
20. Dobler C.C., Korver S., Batbayar O., Nyamdulam B., Oyuntsetseg S., Bold Tsolmon B., Surmaajav B., Bayarjargal B., Marais B.J. Multidrug-resistant tuberculosis among first-line treatment failures in Mongolia. Emerg. Infect. Dis. 2015, 21:1451-1454.
21. Kendall E.A., Fofana M.O., Dowdy D.W. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir. Med. 2015, 3:963-972.
22. Dharmadhikari A.S., Mphahlele M., Venter K., et al. Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 2014, 18:1019-1025.
23. Drobniewski F., Balabanova Y., Nikolayevsky V., et al. Drug-resistant tuberculosis, clinical virulence and the dominance of the Beijing strain family in Russia. JAMA 2005, 293:2726-2731.
24. Merker M., Blin C., Mona S., et al. Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage. Nat. Genet. 2015, 47:242-249.
25. Hanekom M., Gey van Pittius N.C., McEvoy C., et al. Mycobacterium tuberculosis Beijing genotype: a template for success. Tuberculosis 2011, 91:510-523.
26. Marais B.J., Victor T., Hesseling C., et al. Beijing and Haarlem genotype families are over-represented among children with drug resistant tuberculosis in the Western Cape, South Africa. J. Clin. Microbiol. 2006, 44:3539-3543.
27. Islam T., Hiatt T., Hennig C., Nishikiori N. Drug-resistant tuberculosis in the WHO Western Pacific region. Western Pac Surveill Response J 2014, 5:34-46.
28. Islam T., van Weezenbeek C., Vianzon R., et al. Market size and sales pattern of tuberculosis drugs in the Philippines. Public Health Action 2013, 3:337-341.
29. Marais B., Lönnroth K., Lawn S., et al. Tuberculosis co-morbidity with communicable and non-communicable diseases: integrating health services and control efforts. Lancet Infect. Dis. 2013, 13:436-448.
30. Paolo W.F., Nosanchuk J.D. Tuberculosis in New York City: recent lessons and a look ahead. Lancet Infect. Dis. 2004, 4:287-293.
31. Murray E., Bond V., Marais B.J., Godfrey-Faussett P., Ayles H., Beyers N. High levels of vulnerability and anticipated stigma reduce the impetus for tuberculosis diagnosis in Cape Town, South Africa. Health Policy Plan. 2013, 28:410-418.
32. Gandhi N.R., Moll A., Sturm A.W., et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368:1575-1580.
33. Heyns L., Gie R.P., Goussard P., Beyers N., Warren R.M., Marais B.J. Nosocomial transmission of M.tuberculosis in kangaroo mother care units: a risk in tuberculosis endemic areas. Acta Paediatr. 2006, 95:535-539.
34. Sotgiu G., D'Ambrosio L., Centis R., Bothamley G., Cirillo D.M., De Lorenzo S., et al. TB and M/XDR-TB infection control in European TB reference centres: the Achilles' heel?. Eur. Respir. J. 2011, 38:1221-1223.
35. Murray E.J., Marais B.J., Mans G., et al. A multidisciplinary approach to map potential TB transmission 'hot spots' in high burden communities. Int. J. Tuberc. Lung Dis. 2009, 13:767-774.
36. Raviglione M., Marais B., Floyd K., et al. Scaling up of interventions to achieve global tuberculosis control: progress, new developments and update. Lancet 2012, 379:1902-1913.
37. Gurjav U., Burneebaatar B., Narmandah E., Tumenbayar O., Ochirbat B., Hill-Cawthorne G.A., Marais B.J., Sintchenko V. Spatiotemporal evidence for cross-border spread of MDR-TB along the Trans-Siberian Railway line. Int J Tuberc Lung Dis 2015, 19:1376-1382.
38. Zelner J.L., Murray M.B., Becerra M.C., et al. Identifying hotspots of multi-drug resistant tuberculosis transmission using spatial and molecular genetic data. J. Infect. Dis. 2016, 213:287-294.
39. Gurjav U., Jelfs P., Hill-Cawthorne G.A., Marais B.J., Sintchenko V. Genotype heterogeneity within geospatial hotspots suggest foci of imported disease in Sydney, Australia. Infect. Genet. Evol. Jul. 15 2015, (pii: S1567-1348(15)00276-2).
40. Marais B.J., Tadolini M., Zignol M., Migliori G.B. Paediatric TB - lessons from Denmark and inclusive strategies to consider. Eur. Respir. J. 2014, 43:678-684.
41. Coitinho C., Greif G., Robello C., et al. Rapidly progressing tuberculosis outbreak in a very low risk group. Eur. Respir. J. 2014, 43:903-906.
42. Abubakar I., Dara M., Manissero D., Zumla A. Tackling the spread of drug-resistant tuberculosis in Europe. Lancet 2012, 379:e21-e23.
43. Islam T., Marais B.J., Nhung N.V., et al. Western Pacific Regional Green Light Committee: progress and way forward. Int. J. Infect. Dis. 2015, 32:161-165.
44. Lawn S.D., Mwaba P., Bates M., et al. Advances in diagnostic assays for tuberculosis: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect. Dis. 2013, 13:349-361.
45. Ahuja S.D., Ashkin D., Avendano M., et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients. PLoS Med. 2001, 9:e1001300.
46. Migliori G.B., Sotgiu G., Gandhi N.R., et al. Drug resistance beyond XDR-TB: results from a large individual patient data meta-analysis. Eur. Respir. J. 2013, 42:169-179.
47. Van Deun A., Maug A.K.J., Salim M.A.H., et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 2010, 182:684-692.
48. Mitnick C.D., Castro K.G., Harrington M., Sacks L.V., Burman W. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med. 2007, 4:e29.
49. Nachman S., Ahmed A., Amanullah F., et al. Towards earlier inclusion of children in tuberculosis drugs trials: consensus statements from an expert panel. Lancet Infect. Dis. 2015, 15:711-720.
50. Ottenhoff T.H.M. The knowns and unknowns of the immunopathogenesis of tuberculosis. Int. J. Tuberc. Lung Dis. 2012, 16:1424-1432.
51. McShane H., Jacobs W.R., Fine P.E., et al. BCG myths, realities, and the need for alternative vaccine strategies. Tuberculosis 2012, 92:283-288.
52. Hesseling A.C., Cotton M., BJ M., et al. BCG and HIV reconsidered: moving the research agenda forward. Vaccine 2007, 25:6565-6568.
53. Comas I., Chakravartti J., Small P.M., et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat. Genet. 2010, 42:498-503.
54. Supply P., Marceau M., Mangenot S., et al. Genomic analysis of smooth tubercle bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis. Nat. Genet. 2013, 45:172-179.
55. Donald P.R., Marais B.J., Barry C.E. The influence of age on the epidemiology and pathology of tuberculosis. Lancet 2010, 375:1852-1854.
56. Benita-Bivas M., Gillard G.O., Bar L., et al. Airway CD8+ T-cells induced by pulmonary DNA immunization mediate protective anti-viral immunity. Mucosal Immunol. 2013, 6:156-166.
57. Dye C., Glaziou P., Floyd K., Raviglione M. Prospects for tuberculosis elimination. Annu. Rev. Public Health 2013, 34:271-286.